# A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

> **NCT04129554** · PHASE2 · COMPLETED · sponsor: **Janssen Sciences Ireland UC** · enrollment: 130 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** JNJ-73763989
- **DRUG:** JNJ-56136379
- **DRUG:** Placebo for JNJ-73763989
- **DRUG:** Placebo for JNJ-56136379
- **DRUG:** Entecavir (ETV) monohydrate
- **DRUG:** Tenofovir disoproxil fumarate (TDF)
- **DRUG:** Tenofovir alafenamide (TAF)

## Key facts

- **NCT ID:** NCT04129554
- **Lead sponsor:** Janssen Sciences Ireland UC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-06
- **Primary completion:** 2021-07-08
- **Final completion:** 2022-06-09
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04129554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04129554, "A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04129554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*